Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro Statistics

Total Valuation

Alzamend Neuro has a market cap or net worth of $7.95 million. The enterprise value is $5.24 million.

Market Cap	7.95M
Enterprise Value	5.24M

Important Dates

The last earnings date was Wednesday, March 11, 2026, after market close.

Earnings Date	Mar 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Alzamend Neuro has 3.80 million shares outstanding. The number of shares has increased by 762.52% in one year.

Current Share Class	3.80M
Shares Outstanding	3.80M
Shares Change (YoY)	+762.52%
Shares Change (QoQ)	+12.53%
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	6.68%
Float	3.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.64
P/TBV Ratio	3.64
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.99

Current Ratio	1.99
Quick Ratio	1.46
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,008.15

Financial Efficiency

Return on equity (ROE) is -249.97% and return on invested capital (ROIC) is -156.07%.

Return on Equity (ROE)	-249.97%
Return on Assets (ROA)	-107.01%
Return on Invested Capital (ROIC)	-156.07%
Return on Capital Employed (ROCE)	-322.04%
Weighted Average Cost of Capital (WACC)	2.90%
Revenue Per Employee	n/a
Profits Per Employee	-$1.09M
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -66.73% in the last 52 weeks. The beta is -0.25, so Alzamend Neuro's price volatility has been lower than the market average.

Beta (5Y)	-0.25
52-Week Price Change	-66.73%
50-Day Moving Average	2.07
200-Day Moving Average	2.46
Relative Strength Index (RSI)	53.24
Average Volume (20 Days)	69,485

Short Selling Information

The latest short interest is 269,773, so 7.09% of the outstanding shares have been sold short.

Short Interest	269,773
Short Previous Month	263,391
Short % of Shares Out	7.09%
Short % of Float	7.11%
Short Ratio (days to cover)	3.54

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-7.03M
Pretax Income	-7.04M
Net Income	-7.63M
EBITDA	-6.94M
EBIT	-7.03M
Earnings Per Share (EPS)	-$3.03

Balance Sheet

The company has $2.71 million in cash and n/a in debt, with a net cash position of $2.71 million or $0.71 per share.

Cash & Cash Equivalents	2.71M
Total Debt	n/a
Net Cash	2.71M
Net Cash Per Share	$0.71
Equity (Book Value)	2.18M
Book Value Per Share	0.57
Working Capital	1.84M

Cash Flow

In the last 12 months, operating cash flow was -$5.96 million and capital expenditures -$210,000, giving a free cash flow of -$6.17 million.

Operating Cash Flow	-5.96M
Capital Expenditures	-210,000
Free Cash Flow	-6.17M
FCF Per Share	-$1.62

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Alzamend Neuro does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-762.52%
Shareholder Yield	-762.52%
Earnings Yield	-95.98%
FCF Yield	-77.58%

Analyst Forecast

The average price target for Alzamend Neuro is $28.00, which is 1,239.71% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$28.00
Price Target Difference	1,239.71%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 12, 2025. It was a reverse split with a ratio of 1:9.

Last Split Date	May 12, 2025
Split Type	Reverse
Split Ratio	1:9

Scores

Altman Z-Score	n/a
Piotroski F-Score	1